|
124 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
11 Trials |
|
2428 News |
|
| «12...38394041424344454647484950» |
- Selzentry (maraviroc) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Trial initiation date: IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients (clinicaltrials.gov) - Dec 5, 2011
P3, N=17, Completed, Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Initiation date: Oct 2009 --> Jul 2010
- Enrollment change: Treatment De-Intensification and Residual HIV-1 in Youth (clinicaltrials.gov) - Dec 4, 2011
P=N/A, N=34, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Initiation date: Oct 2009 --> Jul 2010 N=50 --> 34
- Trial completion: Treatment De-Intensification and Residual HIV-1 in Youth (clinicaltrials.gov) - Dec 4, 2011
P=N/A, N=34, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
N=50 --> 34 Active, not recruiting --> Completed
- | Veregen (sinecatechins) / Sinphar Pharma, Medigene
New P1 trial: Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers (clinicaltrials.gov) - Dec 1, 2011
P1, N=30, Completed, Sponsor: MediGene
- | valacyclovir / Generic mfg., acyclovir / Generic mfg.
Trial completion: Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV (clinicaltrials.gov) - Dec 1, 2011
P4, N=28, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| darunavir/ritonavir / Generic mfg.
Trial completion: A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN) (clinicaltrials.gov) - Dec 1, 2011
P3, N=590, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA) (clinicaltrials.gov) - Dec 1, 2011
P2, N=72, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Antiretroviral Treatment Simplified Follow-up Management Assessment (ANRS 12110 STRATALL) (clinicaltrials.gov) - Dec 1, 2011
P3, N=459, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Active, not recruiting --> Completed Active, not recruiting --> Completed
- efavirenz / Generic mfg., didanosine / Generic mfg., lamivudine / Generic mfg.
Trial completion: Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME) (clinicaltrials.gov) - Dec 1, 2011
P2, N=52, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| darunavir/ritonavir / Generic mfg.
Trial completion: A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents (clinicaltrials.gov) - Nov 30, 2011
P2, N=80, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Prezista (darunavir) / J&J
Trial completion: TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients (clinicaltrials.gov) - Nov 30, 2011
P3, N=604, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Fuzeon (enfuvirtide) / Roche
Trial termination, Compliance: Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment With Enfuvirtide (Fuzeon) Associated With Two Active Molecules (clinicaltrials.gov) - Nov 27, 2011
P=N/A, N=4, Terminated, Sponsor: University Hospital, Rouen
Active, not recruiting --> Completed Recruiting --> Terminated; difficult to include patients
- Fuzeon (enfuvirtide) / Roche
Enrollment change, Compliance: Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment With Enfuvirtide (Fuzeon) Associated With Two Active Molecules (clinicaltrials.gov) - Nov 27, 2011
P=N/A, N=4, Terminated, Sponsor: University Hospital, Rouen
Recruiting --> Terminated; difficult to include patients N=40 --> 4
- |||||||||| Olysio (simeprevir) / J&J, Medivir
New P3 trial: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1 (clinicaltrials.gov) - Nov 24, 2011
P3, N=109, Completed, Sponsor: Janssen R&D Ireland
- |||| Selzentry (maraviroc) / ViiV Healthcare
Trial completion: A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients (clinicaltrials.gov) - Nov 22, 2011
P2, N=129, Completed, Sponsor: ViiV Healthcare
N=40 --> 4 Active, not recruiting --> Completed
- || New P2/3 trial: Vitamin D Supplementation in HIV (clinicaltrials.gov) - Nov 20, 2011
P2/3, N=58, Active, not recruiting, Sponsor: Children's Hospital of Philadelphia
- |||||||||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P3 trial: Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients (clinicaltrials.gov) - Nov 17, 2011
P3, N=420, Active, not recruiting, Sponsor: Gilead Sciences
- |||| efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion: ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla (clinicaltrials.gov) - Nov 17, 2011
P4, N=115, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cenicriviroc (TBR-652) / Takeda, AbbVie
New P2b trial: Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors (clinicaltrials.gov) - Nov 16, 2011
P2b, N=5, Terminated, Sponsor: University of California, San Francisco
- || emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
New P3 trial: IPERGAY: On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men (clinicaltrials.gov) - Nov 15, 2011
P3, N=1900, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- Vacc-4x / Bionor
New P1/2 trial: Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant (clinicaltrials.gov) - Nov 15, 2011
P1/2, N=24, Completed, Sponsor: Oslo University Hospital
- | emtricitabine / Generic mfg., lopinavir/ritonavir / Generic mfg.
New P4 trial: Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression (clinicaltrials.gov) - Nov 14, 2011
P4, N=336, Recruiting, Sponsor: Juan A. Arnaiz
- |||||||||| Daklinza (daclatasvir) / BMS
New P3 trial, IO biomarker: Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus (clinicaltrials.gov) - Nov 13, 2011
P3, N=300, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- |||| emtricitabine/tenofovir disoproxil fumarate / Generic mfg., abacavir/lamivudine / Generic mfg., abacavir / Generic mfg.
Trial completion: SWIFT: Safety and Efficacy Study of Switching From Epzicom to Truvada (clinicaltrials.gov) - Nov 13, 2011
P4, N=312, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: Appropriate Timing of HAART in Co-infected HIV/TB Patients (clinicaltrials.gov) - Nov 9, 2011
P4, N=156, Terminated, Sponsor: Bamrasnaradura Infectious Diseases Institute
Active, not recruiting --> Completed Recruiting --> Terminated; this study was ended prematurely by ethical committees with a reason of the final outcome was achieved with no longer recruitment was needed.
- Enrollment change: Appropriate Timing of HAART in Co-infected HIV/TB Patients (clinicaltrials.gov) - Nov 9, 2011
P4, N=156, Terminated, Sponsor: Bamrasnaradura Infectious Diseases Institute
Recruiting --> Terminated; this study was ended prematurely by ethical committees with a reason of the final outcome was achieved with no longer recruitment was needed. N=210 --> 156
- Trial completion: Effectiveness of an HIV Prevention Program That Targets the Inner Workings of High-risk Social Networks (clinicaltrials.gov) - Nov 9, 2011
P2, N=852, Completed, Sponsor: Medical College of Wisconsin
N=210 --> 156 Active, not recruiting --> Completed
- | efavirenz / Generic mfg., nevirapine / Generic mfg., rifampicin / Generic mfg.
Trial completion: N2R: Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin (clinicaltrials.gov) - Nov 9, 2011
P3, N=142, Completed, Sponsor: Bamrasnaradura Infectious Diseases Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People (clinicaltrials.gov) - Nov 8, 2011
P1, N=22, Terminated, Sponsor: Medicines Development Limited
Active, not recruiting --> Completed Suspended --> Terminated
- ||| AGS-004 / CoImmune
Enrollment change, Combination therapy: Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV (clinicaltrials.gov) - Nov 8, 2011
P2, N=59, Completed, Sponsor: Argos Therapeutics
Suspended --> Terminated N=34 --> 59
- |||| AGS-004 / CoImmune
Trial completion, Combination therapy: Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV (clinicaltrials.gov) - Nov 8, 2011
P2, N=59, Completed, Sponsor: Argos Therapeutics
N=34 --> 59 Active, not recruiting --> Completed
- | New P4 trial: A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts (clinicaltrials.gov) - Nov 6, 2011
P4, N=242, Not yet recruiting, Sponsor: University of British Columbia
- | Vocabria (cabotegravir oral) / ViiV Healthcare
New P1 trial: A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects (clinicaltrials.gov) - Nov 6, 2011
P1, N=28, Completed, Sponsor: ViiV Healthcare
- Pifeltro (doravirine) / Merck (MSD)
New P1 trial: A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005) (clinicaltrials.gov) - Nov 6, 2011
P1, N=18, Completed, Sponsor: Merck
- | Trial completion: Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis (clinicaltrials.gov) - Nov 6, 2011
P3, N=150, Completed, Sponsor: All India Institute of Medical Sciences, New Delhi
Active, not recruiting --> Completed Recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: Drug Interaction Study Between Dolutegravir and Prednisone (clinicaltrials.gov) - Nov 3, 2011
P1, N=12, Completed, Sponsor: ViiV Healthcare
Recruiting --> Completed Active, not recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
New P1 trial: Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study. (clinicaltrials.gov) - Nov 2, 2011
P1, N=11, Completed, Sponsor: ViiV Healthcare
- | Trial completion, Enrollment change: Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=200 --> 24 | Recruiting --> Completed
- Trial completion: Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=24, Completed, Sponsor: National Cancer Institute (NCI)
N=200 --> 24 | Recruiting --> Completed Recruiting --> Completed
- Selzentry (maraviroc) / ViiV Healthcare
Trial termination, IO biomarker: Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens (clinicaltrials.gov) - Oct 30, 2011
P4, N=48, Terminated, Sponsor: St Stephens Aids Trust
Recruiting --> Completed Recruiting --> Terminated; The data from the first 48 patients recruited has now been analysed, and it has been determined that it is sufficient to meet the study objectives.
- Selzentry (maraviroc) / ViiV Healthcare
Enrollment change, IO biomarker: Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens (clinicaltrials.gov) - Oct 30, 2011
P4, N=48, Terminated, Sponsor: St Stephens Aids Trust
Recruiting --> Terminated; The data from the first 48 patients recruited has now been analysed, and it has been determined that it is sufficient to meet the study objectives. N=92 --> 48
- New P4 trial: Atazanavir/Ritonavir and Zinc Pharmacokinetic Study (clinicaltrials.gov) - Oct 30, 2011
P4, N=16, Completed, Sponsor: St Stephens Aids Trust
- Trial completion: Interactions Between Antiretrovirals (ARVs) and Combined Oral Contraceptives (COCs) (clinicaltrials.gov) - Oct 27, 2011
P4, N=370, Completed, Sponsor: FHI 360
N=92 --> 48 Active, not recruiting --> Completed
- Fuzeon (enfuvirtide) / Roche, Isentress (raltegravir) / Merck (MSD)
Trial completion: RAL-eve Study: Raltegravir Substitution Study (clinicaltrials.gov) - Oct 26, 2011
P=N/A, N=14, Completed, Sponsor: Stanford University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial withdrawal: Raltegravir Activity In Lymphoid Tissues (clinicaltrials.gov) - Oct 24, 2011
P=N/A, N=10, Withdrawn, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed Active, not recruiting --> Withdrawn
- Trial completion: Effects of Endocrine Health on Mental Performance of Men and Women Using Drugs (clinicaltrials.gov) - Oct 24, 2011
P=N/A, N=300, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Withdrawn Recruiting --> Completed
- | tenofovir vaginal gel (GS-1278 gel) / Gilead, CONRAD
Enrollment open: Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection (clinicaltrials.gov) - Oct 23, 2011
P3, N=2900, Recruiting, Sponsor: CONRAD
Recruiting --> Completed Not yet recruiting --> Recruiting
- Tivicay (dolutegravir) / ViiV Healthcare
Enrollment change: Drug Interaction Study Between Dolutegravir and Prednisone (clinicaltrials.gov) - Oct 20, 2011
P1, N=12, Completed, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting N=24 --> 12
- | New P4 trial: Early Antiviral Therapy for Critically Ill HIV Infected Patients (clinicaltrials.gov) - Oct 18, 2011
P4, N=344, Recruiting, Sponsor: Hospital Nossa Senhora da Conceicao
- Trial completion: Healthy Teen Girls: HIV Risk Reduction (clinicaltrials.gov) - Oct 18, 2011
P1/2, N=333, Completed, Sponsor: Mississippi State University
N=24 --> 12 Active, not recruiting --> Completed